Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates

Curr Opin Pharmacol. 2002 Oct;2(5):567-73. doi: 10.1016/s1471-4892(02)00204-7.


Protein kinases have been identified as being implicated in many diseases, and the launch of the anti-cancer Bcr/Abl-kinase inhibitor Glivec has been a major advance in validating protein kinases as 'druggable' targets. High-resolution data exists for many classes of protein kinases and, in some cases, these structures are co-complexed with an inhibitor and/or substrate mimic. Coupled with the increasing reliability of computational predictions, structure-based design is now playing an increasingly important role in the discovery and optimisation of novel, potent and selective protein kinase inhibitors.

Publication types

  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Binding Sites
  • Crystallography
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Molecular Sequence Data
  • Pharmacology / trends*
  • Protein Conformation
  • Protein Kinase Inhibitors*
  • Protein Kinases / chemistry
  • Structure-Activity Relationship


  • Enzyme Inhibitors
  • Protein Kinase Inhibitors
  • Protein Kinases